- Home
- DGII vs TRVI Comparison
DGII vs TRVI Comparison
Compare DGII & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGII
- TRVI
- Stock Information
- Founded
- DGII 1985
- TRVI 2011
- Country
- DGII United States
- TRVI United States
- Employees
- DGII N/A
- TRVI N/A
- Industry
- DGII Computer peripheral equipment
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- DGII Technology
- TRVI Health Care
- Exchange
- DGII Nasdaq
- TRVI Nasdaq
- Market Cap
- DGII 1.3B
- TRVI 1.1B
- IPO Year
- DGII N/A
- TRVI 2019
- Fundamental
- Price
- DGII $38.14
- TRVI $10.58
- Analyst Decision
- DGII Buy
- TRVI Strong Buy
- Analyst Count
- DGII 4
- TRVI 9
- Target Price
- DGII $38.75
- TRVI $20.72
- AVG Volume (30 Days)
- DGII 141.4K
- TRVI 1.6M
- Earning Date
- DGII 11-12-2025
- TRVI 11-10-2025
- Dividend Yield
- DGII N/A
- TRVI N/A
- EPS Growth
- DGII 147.46
- TRVI N/A
- EPS
- DGII 1.14
- TRVI N/A
- Revenue
- DGII $420,935,000.00
- TRVI N/A
- Revenue This Year
- DGII $2.46
- TRVI N/A
- Revenue Next Year
- DGII $7.51
- TRVI N/A
- P/E Ratio
- DGII $33.98
- TRVI N/A
- Revenue Growth
- DGII N/A
- TRVI N/A
- 52 Week Low
- DGII $22.39
- TRVI $2.36
- 52 Week High
- DGII $39.62
- TRVI $11.11
- Technical
- Relative Strength Index (RSI)
- DGII 58.43
- TRVI 59.71
- Support Level
- DGII $38.33
- TRVI $10.37
- Resistance Level
- DGII $39.62
- TRVI $10.90
- Average True Range (ATR)
- DGII 1.07
- TRVI 0.51
- MACD
- DGII 0.06
- TRVI -0.07
- Stochastic Oscillator
- DGII 78.04
- TRVI 60.16
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.